With LentiGlobin cleared by FDA, bluebird lifts EU marketing hold on gene therapy using the same delivery mechanism

With the FDA finally off its back on its LentiGlobin sickle cell program, bluebird bio is heading into its big split-up with a mostly …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With Lenti­Glo­bin cleared by FDA, blue­bird lifts EU mar­ket­ing hold on gene ther­a­py us­ing the same de­liv­ery mech­a­nism